In conclusion, our in vitro and in vivo data indicate that TOX acts as a CRC tumor suppressor to inhibit tumorigenesis and metastasis, and rapamycin or combined with PD1 inhibition may be a promising treatment for CRC. Here, PDCD1 is linked to colorectal carcinoma.